Post-transcriptional and post-translational regulation of Bcl2
- 24 November 2010
- journal article
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 38 (6), 1571-1575
- https://doi.org/10.1042/bst0381571
Abstract
Bcl2 is an important pro-survival protein that has an essential function in normal immunity and whose constitutive expression leads to the development of lymphomas. Although transcriptional control of Bcl2 has been reported, increasing evidence suggests an important component of Bcl2 regulation is post-transcriptional. Phosphorylation of Bcl2 has been shown to enhance activity to allow response to extracellular growth-factor-mediated signals. Bcl2 mRNA contains regulatory elements in both its 5′- and 3′-UTRs (untranslated regions). An IRES (internal ribosome entry sequence) in the 5′-UTR permits continued translation in the presence of cellular stresses that reduce cap-dependent translation. The 3′-UTR of Bcl2 mRNA is 5.2 kb in length and contains multiple predicted miRNA (microRNA) and RNA-BP (RNA-binding protein)-binding sites. miR-15a and miR-16-1 have been found to inhibit Bcl2 expression in B-cells, whereas the RNA-BP nucleolin has been shown to increase Bcl2 expression by binding to the 3′-UTR and enhancing mRNA stability. Both decreased expression of miR-15a and miR-16-1 and increased nucleolin have been shown to be associated with increased Bcl2 expression and resistance to apoptosis in the common human disease, chronic lymphocytic leukaemia. miRNA-based therapeutic approaches to treat cancer are emerging. Bcl2 is highly regulated by miRNAs and is therefore an excellent candidate for such approaches.This publication has 49 references indexed in Scilit:
- BCL2 protein expression parallels its mRNA level in normal and malignant B cellsBlood, 2004
- Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functionsProceedings of the National Academy of Sciences of the United States of America, 2003
- Expression of Bcl-2 Protein and Bcl-2 mRNA in Normal and Neoplastic Lymphoid TissuesLeukemia & Lymphoma, 1994
- Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissuesBlood, 1993
- Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridizationBlood, 1992
- bcl-2 transgene inhibits T cell death and perturbs thymic self-censorshipCell, 1991
- Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.Proceedings of the National Academy of Sciences of the United States of America, 1991
- Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cellsNature, 1988
- Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocationCell, 1986
- Cloning of the Chromosome Breakpoint of Neoplastic B Cells with the t(14;18) Chromosome TranslocationScience, 1984